Close Menu

NEW YORK – Molecular diagnostic firm Inflammatix announced Tuesday it has received up to $1.1 million from the US Department of Defense's Defense Advanced Research Projects Agency (DARPA) to further develop a rapid diagnostic to predict risk of severe respiratory failure in patients with COVID-19.

The company's CoVerity COVID-19 Severity test is being developed to help clinicians make hospital admission and resourcing decisions. Its host-response diagnostics technology reads the immune system with a machine learning algorithm and 5 mRNA biomarkers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.